Streetbeat News

Analyst Ratings

NCLH

Over the past 3 months, 10 analysts have published their opinion on Norwegian Cruise Line (NYSE:NCLH) stock. The average price target for the stock is $19.0, an increase of 16.49% from the previous average price target of $16.31. The ratings include 1 bullish, 7 indifferent, and 2 somewhat bearish.

Portfolio Pulse from Benzinga Insights

August 18, 2023 | 7:00 pm

TVTX

Analysts have provided various ratings for Travere Therapeutics (NASDAQ:TVTX) within the last quarter, with a total of 3 bullish, 3 somewhat bullish, and 2 indifferent ratings. The average price target is $27.75, representing an upside from the current price of $13.725. However, this average represents a 4.31% decrease from the previous average price target of $29.00.

Portfolio Pulse from Benzinga Insights

August 18, 2023 | 7:00 pm

COF

Capital One Financial's (NYSE:COF) short percent of float has decreased by 3.83% since its last report, with 7.57 million shares sold short, representing 2.01% of all regular shares available for trading. This decrease in short interest could indicate a more bullish market sentiment towards the company. Compared to its peers, Capital One has less short interest, with the peer group average at 7.95%.

Portfolio Pulse from Benzinga Insights

August 18, 2023 | 7:00 pm

QLYS

Stephens analyst Brian Colley initiated coverage on Qualys, Inc. (NASDAQ:QLYS) with an Equal-Weight rating and a price target of $145. QLYS has expanded its vulnerability management capabilities and entered large markets like EDR, XDR, and CNAPP. However, growth has lagged behind security peers as the company has focused more on profitability. The analyst sees potential for growth but also warns of elevated competitive risks and a possible slowdown in security spending.

Portfolio Pulse from Nabaparna Bhattacharya

August 18, 2023 | 6:46 pm

VRTX

Vertex Pharmaceuticals' (NYSE:VRTX) short percent of float has risen 13.27% since its last report, with 2.86 million shares sold short, which is 1.11% of all regular shares available for trading. It would take traders 2.11 days to cover their short positions on average. An increase in short interest can signal that investors have become more bearish. Vertex Pharmaceuticals' peer group average for short interest as a percentage of float is 3.21%, which means the company has less short interest than most of its peers.

Portfolio Pulse from Benzinga Insights

August 18, 2023 | 6:45 pm

HSY

Hershey's (NYSE:HSY) short percent of float has fallen 14.66% since its last report, with 3.05 million shares sold short, which is 2.27% of all regular shares available for trading. It would take traders 2.1 days to cover their short positions on average. Hershey's peer group average for short interest as a percentage of float is 4.72%, indicating less short interest than most of its peers.

Portfolio Pulse from Benzinga Insights

August 18, 2023 | 6:45 pm

HSAI

Goldman Sachs has downgraded Hesai Group's stock from Buy to Neutral, leading to a decrease in the company's share price.

Portfolio Pulse from Benzinga Newsdesk

August 18, 2023 | 6:40 pm

BLBD

BofA Securities initiated coverage on Blue Bird Inc (NASDAQ:BLBD) with a Buy rating and a price target of $26.50. The analyst noted that Blue Bird has successfully revamped its financial metrics and is poised to dominate the school bus electrification market. The company anticipates over $1 billion in revenue from the EPA's clean school bus initiative. Blue Bird's backlog includes firm EV orders worth approximately $180 million.

Portfolio Pulse from Vandana Singh

August 18, 2023 | 6:25 pm

CRVS

Oppenheimer has initiated coverage on Corvus Pharmaceuticals Inc (NASDAQ:CRVS) with an Outperform rating and a price target of $7.00. The company plans to expand soquelitinib trials into larger oncology indications, including clear cell renal cell carcinoma. Corvus Pharmaceuticals revealed updated data from the Phase 1/1b trial evaluating single-agent therapy with CPI-818 in patients with relapsed T cell lymphomas. The company's cash reserve of $37 million is expected to fund operations until mid-2024.

Portfolio Pulse from Vandana Singh

August 18, 2023 | 6:24 pm

CTLT

REGN

Traders are circulating a note from RBC suggesting that Catalent should see a significant increase following the FDA approval of Regeneron. This is likely due to Catalent's involvement in the production of Regeneron's products.

Portfolio Pulse from Benzinga Newsdesk

August 18, 2023 | 6:23 pm